Dojin Cancer Immunology Research Institute

What Dojin Cancer Immunology Research Institute does

Dojin Cancer Immunology Research Institute (株式会社同仁がん免疫研究所) is a privately held Japanese regenerative-medicine company founded in Kumamoto in January 2013, focused on cancer immunotherapy. The company has developed and patented a Hexa-complex Immunotherapy (6種複合免疫療法) in which six immune cell types — Helper T cells, Killer T cells, NK cells, NKT cells, Gamma-delta T cells, and Dendritic cells — are simultaneously co-cultured from a single patient blood draw and expanded from 10–20 million cells to 20–50 billion cells over roughly three weeks. The proprietary co-culture method is protected by Japan Patent No. 4953403 and Korea Patent No. 10-1299299; a separate patent (No. 6052756) covers circulating tumor cell detection. Anti-tumor effectiveness of the CD3/CD161 co-stimulation approach has been peer-reviewed in Scientific Reports (2023).

The company operates a Cell Processing Center (CPC) in Kumamoto licensed by Japan's Ministry of Health, Labour and Welfare (Facility number FA7150002), which performs cell culture, processing, storage, and management on behalf of medical institutions. Its commercial model is a B2B channel-partner go-to-market: the company does not sell directly to patients. Instead, it provides its proprietary cell culture technology and treatment protocol to a network of 80+ partner medical institutions (提携医療機関) spanning all eight regions of Japan (Hokkaido, Kanto, Tokai, Hokuriku, Kansai, Chugoku, Shikoku, Kyushu-Okinawa). Partner clinics — including group-affiliated Dojin Clinics in Kumamoto, Yokohama, and Fukuoka — administer the therapy to cancer patients, and pricing is settled directly between the patient and the partner clinic. The company earns revenue from cell culture and processing services (professional services) and from provision/licensing of its regenerative-medicine technology to medical institutions. The company is led by Representative Director Ueno Koma (上野景真) with Medical Advisor Nishikawa Shinichi (西川伸一), Professor Emeritus of Kyoto University.

Name

Dojin Cancer Immunology Research Institute

Legal name

株式会社同仁がん免疫研究所

Website

https://dici.co.jp

Company type

Private

Founded year

2013

Operating status

Operating

Short description

Dojin Cancer Immunology Research Institute is a Kumamoto-based private Japanese regenerative-medicine company that operates a licensed Cell Processing Center and provides its patented Hexa-complex Immunotherapy — a 6-type immune cell co-culture cancer treatment — to 80+ partner medical institutions across Japan.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Regenerative Cellular Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro industry

PRIMARYHLAAABAJ

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAGABAD

Cell Therapy CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAIAAAC

Oncology & Hematology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAAABAD

NK Cell Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

• Cancer immunotherapy services
• Regenerative medicine technologies
• Cell processing services
• Immune cell culturing
• Cell therapy licensing

Headquarters

HQ city

Kumamoto

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Cell culture and processing services: The company operates a licensed CPC (Cell Processing Center) that accepts cell culture and processing requests from medical institutions across Japan. Cells are cultured, processed, and managed for partner hospitals and clinics offering the 6-type combined immunotherapy treatment to patients.
2. Regenerative medicine technology provision: Provision of proprietary regenerative medicine and immunotherapy technologies to partner medical institutions. The company licenses its treatment protocols and provides cultured immune cells for patient administration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Dojin Cancer Immunology Research Institute operates a Ministry-licensed Cell Processing Center (CPC) in Kumamoto, Japan, that cultures and processes immune cells for partner medical institutions. Its core service is the Hexa-complex Immunotherapy (6種複合免疫療法), in which six immune cell types (Helper T, Killer T, NK, NKT, Gamma-delta T, and Dendritic cells) are simultaneously co-cultured from a patient's own blood and infused back to attack cancer cells and cancer stem cells. The company licenses its treatment protocols and provides the cultured cells to 80+ partner clinics nationwide, where patients receive the treatment.

Product overview

Dojin Cancer Immunology Research Institute offers a unified cancer immunotherapy treatment service centered on its Hexa-complex Immunotherapy (6種複合免疫療法). The company operates a Cell Processing Center (CPC) facility licensed by Japan's Ministry of Health, Labour and Welfare, providing regenerative medicine-based immunotherapy services through a network of partner medical institutions nationwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Hexa-complex Immunotherapy (6種複合免疫療法) A cancer immunotherapy service in which six immune cell types (Helper T, Killer T, NK, NKT, Gamma-delta T, and Dendritic cells) are simultaneously co-cultured from the patient's own blood over approximately 3 weeks (expanding from 10–20 million to 20–50 billion cells) and reinfused to attack cancer cells and cancer stem cells. Delivered via 80+ partner medical institutions across Japan.
• Cell Processing and Culture Services (CPC) Centralized cell culture, processing, storage, and management service operated from the company's CPC (Culture Center II) in Kumamoto. Licensed by Japan's Ministry of Health, Labour and Welfare, the CPC accepts cell culture commissioned work from medical institutions nationwide.

Quantifiable outcome

• 1,000–2,000万個 → 20–50億個 cells in ~3 weeks culture (1,000x to 2,500x proliferation)
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

34 partnerships are on record, tiered minor and core.

• Ashida ClinicminorChannel Partner/ Reseller/ Distributor · 20 October 2025Located in Nishinomiya City, Hyogo Prefecture. Added as partner in October 2025.
• Dojin Clinic Kumamoto (同仁クリニック 熊本院)coreChannel Partner/ Reseller/ Distributor · 10 October 2025Located in Kumamoto City. Group-affiliated clinic offering the 6-type combined immunotherapy. Added as partner in October 2025.
• Dojin Clinic Yokohama (同仁クリニック 横浜院)coreChannel Partner/ Reseller/ Distributor · 20 August 2025Located in Kanagawa Prefecture, Yokohama. Group-affiliated clinic offering the 6-type combined immunotherapy. Added as partner in August 2025.
• Kinaga Internal Medicine & Endoscopy Clinic (きなが内科・内視鏡クリニック)minorChannel Partner/ Reseller/ Distributor · 2 July 2025Located in Nada-ku, Kobe, Hyogo Prefecture. Added as partner in July 2025.
• Nakai Home Care Clinic (なかいホームケアクリニック)minorChannel Partner/ Reseller/ Distributor · 9 June 2025Located in Nishi-ku, Sakai City, Osaka. Added as partner in June 2025.
• Clinic Shinsei (クリニック新生)minorChannel Partner/ Reseller/ Distributor · 2 June 2025Located in Saga City, Saga Prefecture. Added as partner in June 2025.
• Nakayama Clinic (中山クリニック)minorChannel Partner/ Reseller/ Distributor · 28 May 2025Located in Itami City, Hyogo Prefecture. Added as partner in May 2025.
• Kyobashi Lifestyle Heart Clinic (京橋ライフスタイル・ハートクリニック)minorChannel Partner/ Reseller/ Distributor · 27 May 2025Located in Kyobashi, Tokyo. Added as partner medical institution in May 2025.
• GENE Osaka Clinic (GENE大阪クリニック)minorChannel Partner/ Reseller/ Distributor · 18 April 2025Located in Kita-ku, Osaka. Added as partner in April 2025.
• Sawada Liver & Gastroenterology Clinic (澤田肝臓・消化器内科クリニック)minorChannel Partner/ Reseller/ Distributor · 7 March 2025Located in Takarazuka City, Hyogo Prefecture. Added as partner in March 2025.
• Renais Clinic Nihonbashi (ルネスクリニック日本橋)minorChannel Partner/ Reseller/ Distributor · 14 February 2025Located in Nihonbashi, Tokyo. Added as partner in February 2025.
• Elula Clinic (エルーラクリニック)minorChannel Partner/ Reseller/ Distributor · 31 January 2025Located in Shimogyo-ku, Kyoto. Added as partner in February 2025.
• Musashi Internal Medicine Clinic (むさし内科クリニック)minorChannel Partner/ Reseller/ Distributor · 15 January 2025Located in Kumamoto City. Provides the 6-type combined immunotherapy in the Kyushu region. Added as partner in January 2025.
• Heiwa Clinic (平和医院)minorChannel Partner/ Reseller/ Distributor · 27 December 2024Located in Azabu-Dai, Minato-ku, Tokyo. Added as partner in December 2024.
• Chigusa Clinic (ちぐさクリニック)minorChannel Partner/ Reseller/ Distributor · 18 December 2024Located in Ichihara City, Chiba Prefecture. Added as partner in December 2024.
• GENE Tokyo Clinic (GENE東京クリニック)minorChannel Partner/ Reseller/ Distributor · 4 December 2024Located in Ginza, Tokyo. Added as partner in December 2024.
• Kamada Medical Clinic (鎌田医院)minorChannel Partner/ Reseller/ Distributor · 3 December 2024Located in Mitaka City, Tokyo. Added as partner in December 2024.
• Akane Dotonbori Clinic (茜道頓堀クリニック)minorChannel Partner/ Reseller/ Distributor · 29 November 2024Located in Chuo-ku, Osaka. Added as partner in November 2024.
• Ogura Internal Medicine & Kidney Clinic (おぐら内科・腎クリニック)minorChannel Partner/ Reseller/ Distributor · 3 July 2024Located in Oyama City, Tochigi Prefecture. Added as partner in July 2024.
• Ohji Clinic (おうじクリニック)minorChannel Partner/ Reseller/ Distributor · 22 April 2024Located in Kurashiki City, Okayama Prefecture. Added as partner in April 2024.
• Forebo Ise Internal Medicine & Skin Clinic (の森本内科・循環器科 / 現: の森本内科・スキンクリニック)minorChannel Partner/ Reseller/ Distributor · 15 April 2024Located in Ise City, Mie Prefecture. Added as partner in April 2024.
• Horm Clinic (ホルムクリニック)minorChannel Partner/ Reseller/ DistributorLocated in Sapporo, Hokkaido. Provides the 6-type combined immunotherapy (Hexa-complex Immunotherapy) to patients in the Hokkaido region. Partner medical institution.
• Hibikinomori Clinic (響きの杜クリニック)minorChannel Partner/ Reseller/ DistributorLocated in Sapporo, Hokkaido. Provides the 6-type combined immunotherapy to patients in the Hokkaido region. Added as partner in March 2025.
• Immunus Clinic Nihonbashi (イミュナスクリニック日本橋)minorChannel Partner/ Reseller/ DistributorLocated in Tokyo's Nihonbashi district. Provides the 6-type combined immunotherapy to patients in the Kanto region.
• Fire Clinic Ginza (ファイヤークリニック銀座院)minorChannel Partner/ Reseller/ DistributorLocated in Ginza, Tokyo. Provides the 6-type combined immunotherapy. Added as partner in August 2025.
• Fujimori Internal Medicine Clinic (富士森内科クリニック)minorChannel Partner/ Reseller/ DistributorLocated in Hachioji City, Tokyo. Kanto region partner medical institution.
• Shibaniishi Medical Clinic (芝西医院)minorChannel Partner/ Reseller/ DistributorLocated in Kawaguchi City, Saitama Prefecture. Kanto region partner medical institution.
• Soulage Internal Medicine Clinic (スラージュ内科クリニック)minorChannel Partner/ Reseller/ DistributorLocated in Inage-ku, Chiba. Added as partner in July 2024.
• Elm Clinic (エルムクリニック)minorChannel Partner/ Reseller/ DistributorLocated in Iida City, Nagano Prefecture. Added as partner in September 2024.
• Naruyama Hidamari Clinic (成山ひだまりクリニック)minorChannel Partner/ Reseller/ DistributorLocated in Kaifu District, Aichi Prefecture. Added as partner in April 2025.
• AMIRI CLINICminorChannel Partner/ Reseller/ DistributorLocated in Chuo-ku, Osaka. Added as partner in December 2025.
• Riyo Medical Clinic (Riyoメディカルクリニック)minorChannel Partner/ Reseller/ DistributorLocated in Kita-ku, Osaka. Added as partner in January 2025.
• Take Family Internal Medicine Clinic (竹ファミリー内科クリニック)minorChannel Partner/ Reseller/ DistributorLocated in Kagoshima City. Added as partner in January 2025.
• Dojin Clinic Fukuoka (同仁クリニック 福岡院)coreChannel Partner/ Reseller/ DistributorLocated in Fukuoka City. Group-affiliated clinic offering the 6-type combined immunotherapy.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• JCR Pharmaceuticals Co., Ltd. Japanese specialty biopharmaceutical company with regenerative medicine and cell therapy capabilities, including partnerships in iPS-cell-derived and autologous cell therapies. A larger Japanese player in adjacent cell therapy categories.
• Novartis (Kymriah / T-Charge platform): Global pharmaceutical company with the first commercially approved CAR-T cell therapy (Kymriah) for cancer. Broad incumbent in the cancer cell therapy space; relevant as a global benchmark for commercial autologous cell therapy but at far larger scale and with different technology.
• Takara Bio Inc. Major Japanese biotech and cell therapy CDMO with manufacturing infrastructure, cell processing capabilities, and partnerships for cancer immunotherapy. Broader and more diversified, but overlaps materially in cell therapy manufacturing technology and Japanese distribution.
• Resonac Holdings (formerly Hitachi Chemical / Showa Denko Materials): Operates one of the largest cell therapy CDMO businesses globally (formerly Hitachi Chemical's regenerative medicine business), supplying cell manufacturing services for autologous and allogeneic cell therapies including cancer immunotherapies. Comparable as a cell therapy manufacturing peer at much larger scale.

Regional players

• Rohto Pharmaceutical Co., Ltd. Japanese pharmaceutical company with investments in regenerative medicine and cell therapy (including subsidiary activities in autologous cell processing). Comparable as a Japanese-domiciled player with cell therapy commercial activity, though operating at much larger scale across other pharma categories.

Emerging players

• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T-cell therapies (SPEAR T-cells) for solid tumors. Comparable as a cancer cell therapy developer targeting solid tumors, though differentiated by its engineered TCR approach versus Dojin's autologous multi-cell mix.
• Fate Therapeutics: Clinical-stage cell therapy company developing off-the-shelf NK and T-cell cancer immunotherapies from engineered iPSC-derived cell products. Comparable in the multi-cell-type cancer immunotherapy category, though at a more advanced clinical stage and with a different manufacturing model.
• Tessa Therapeutics: Clinical-stage cell therapy company developing autologous and allogeneic cancer immunotherapies including NK cell and T-cell based therapies. Comparable in therapeutic approach (multi-cell-type immune attack on cancer) but operating at a more advanced clinical stage in international markets.

Direct peers

• Medinet Co., Ltd. Japanese cell therapy company operating a CPC-like model providing immune cell therapy products (e.g., expanded activated lymphocytes) to partner medical institutions for cancer treatment. Most directly comparable Japanese peer by business model, scale, and clinical positioning.
• BrightPath Biotherapeutics: Japanese clinical-stage biotech developing autologous cancer immunotherapy cell products, including dendritic cell and multi-type immune cell therapies. Direct peer in Japanese autologous cancer immunotherapy development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dojin Cancer Immunology Research Institute